TargetMol

Citalopram hydrobromide

Product Code:
 
TAR-T1483
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1483-10mg10mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1483-50mg50mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1483-100mg100mg£160.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1483-200mg200mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Citalopram, a selective serotonin reuptake inhibitor (SSRI), selectively inhibits the CNS neuronal reuptake of serotonin, thereby potentiating serotonergic activity in the central nervous system (CNS). Citalopram Hydrobromide is the orally bioavailable hydrobromide salt of the racemic bicyclic phthalene derivative citalopram with antidepressant activity. This agent has minimal effects on the CNS neuronal reuptake of norepinephrine (NE) and dopamine (DA).
CAS:
59729-32-7
Formula:
C20H22BrFN2O
Molecular Weight:
405.311
Pathway:
Autophagy; Neuroscience; GPCR/G Protein
Purity:
0.9986
SMILES:
Br.CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1
Target:
5-HT Receptor; Serotonin Transporter; Autophagy

References

1. Hyttel J. Prog Neuropsychopharmacol Biol Psychiatry. 1982, 6(3):277-95. 2. Pollier F, et al. Neuropsychopharmacology. 2000, 22(1):64-76. 3. Durham E, et al. PLoS One. 2015, 10(10):e0139719.